UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 28, 2023, Mark Chin informed management that he would be resigning as a member of the Board of Directors of Iterum Therapeutics plc (the "Company") with effect from December 31, 2023. In his discussion with management regarding the reason for his resignation, Mr. Chin stated that he wished to reduce the overall number of public boards on which he currently serves, as a result of a new job, and it is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company thanks Mr. Chin for his service as a member of the Company's Board of Directors for more than six and a half years.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Iterum Therapeutics plc |
|
|
|
|
Date: |
December 29, 2023 |
By: |
/s/ Corey N. Fishman |
|
|
|
Chief Executive Officer |
Document And Entity Information |
Dec. 29, 2023 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Dec. 28, 2023 |
| Entity Registrant Name | Iterum Therapeutics plc |
| Entity Central Index Key | 0001659323 |
| Entity Emerging Growth Company | true |
| Entity File Number | 001-38503 |
| Entity Incorporation, State or Country Code | L2 |
| Entity Tax Identification Number | 00-0000000 |
| Entity Address, Address Line One | Fitzwilliam Court |
| Entity Address, Address Line Two | 1st Floor |
| Entity Address, Address Line Three | Leeson Close |
| Entity Address, City or Town | Dublin 2 |
| Entity Address, Country | IE |
| Entity Address, Postal Zip Code | Not applicable |
| City Area Code | +353 |
| Local Phone Number | 1 6694820 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Entity Ex Transition Period | true |
| Title of 12(b) Security | Ordinary Shares, par value $0.01 per share |
| Trading Symbol | ITRM |
| Security Exchange Name | NASDAQ |
&PO M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #&@YU799!YDAD! M #/ P $P @ 'V$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+ 4!08 "0 ) #X" ! % ! end